Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. Cripps
P1.01-80 ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients With EGFRm and NSCLC Treated With Osimertinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA10.05 an Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients With Uncommon EGFR Mutation(KCSG-Lu15-09)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-98 a Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients With Brain Metastases or Dose Reductions
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC With Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients With EGFR T790m-Positive NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-32 a Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary